Lesstopy, a leading Korean atopic dermatitis care brand, has successfully been registered at Singapore’s Health Sciences Authority (HSA)
(Isstories Editorial):- Singapore, Singapore Sep 12, 2025 (Issuewire.com) – Lesstopy, a leading Korean eczema care brand, has successfully been registered at Singapore’s Health Sciences Authority (HSA), marking a significant milestone in its Southeast Asian market expansion.
More on Isstories:
- ThreatHunter.ai Calls Out the Second MFA Lie: “Compliance Says MFA = Job Done”
- OTT Car Care Elevates Automotive Experiences with Car Launch Event Expertise and Manufacturer Tours
- How Much Does A Hoverboard Cost: Navigating Prices and Options
- Print Media Association Data Breach May Expose Social Security, ID – Financial Records
- Katie Lory, Recognized by BestAgents.us as a 2025 Top Agent
The newly HSA-registered Lesstopy ATO Cream features patented Lycopus Lucidus Leaf Extract as its core ingredient, recognized for its ability to gently soothe and calm sensitive, irritated skin. The premium formula contains 23% certified organic ingredients, creating a gentle and safe formulation for users.
Lesstopy has already established itself as a prominent eczema care brand in South Korea, with presence in 11 major department stores including Shinsegae and Lotte. The brand has gained explosive popularity among Korean consumers, positioning itself as “a new standard for premium eczema care” and building trust through word-of-mouth recommendations and high repurchase rates.
The HSA registration represents more than just regulatory compliance – it signifies that customers can use the product with greater confidence. As Singapore’s cosmetics regulatory authority, HSA registration demonstrates that Lesstopy has secured international-level quality control and safety standards. “HSA registration is a testament to the reliability and safety of our products,” a Lesstopy spokesperson said. “We are committed to delivering premium skincare solutions that consumers can trust.”
Lesstopy has validated the anti-inflammatory and soothing effects of its patented Lycopus Lucidus Leaf Extract through comprehensive dermatological testing. Beyond basic ingredient testing, the company conducted more than 10 clinical and non-clinical trials targeting major concerns of atopic skin, including skin barrier strengthening, redness reduction, and itch relief. “Our research shows that the extract not only reduces irritation but also strengthens the skin barrier, providing safe and effective care for sensitive skin,” the spokesperson added.
The HSA registration marks an important milestone as the Korean brand, already successfully established domestically, opens new possibilities on the international stage. Based on its verified quality that passed stringent regulations and innovative technology, Lesstopy aims to become a trusted new option for Singapore consumers. Starting this year, the company will operate a Singapore-dedicated online store, making Lesstopy products more easily accessible to local consumers.
The market entry underscores the brand’s commitment to bringing proven Korean skincare innovation to Southeast Asian consumers seeking effective, scientifically backed eczema care solutions.
This article was originally published by IssueWire. Read the original article here.
